A new analysis of the SELECT trial has shown that treatment with once-weekly semaglutide 2.4 mg significantly reduced hospital admissions for all causes, not just cardiac-related, in people with overweight/obesity and established cardiovascular disease. Semaglutide also reduced overall hospitalization time. The study found that those treated with semaglutide were less likely to be hospitalized for any reason, including cardiovascular disorders, infections, and surgical procedures. The cost-saving potential of semaglutide was highlighted, with reductions in total hospitalizations leading to a decrease in overall days spent in the hospital. However, caution was advised in interpreting the results due to potential biases from drug company funding.
Source link
Semaglutide 2.4 mg Reduces All-Cause Hospital Admissions
